Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.

Abstract

9004 Background: Given the importance of molecular testing and targeted therapy for mNSCLC, the MYLUNG (Molecularly Informed Lung Cancer Treatment in a Community Cancer Network) consortium pragmatic study assessed real-world biomarker testing rates and turnaround times (TAT) within The US Oncology Network of over 1,000 providers across the United States. Methods: This was a retrospective observational chart review study of pts with mNSCLC initiating first-line (1L) systemic therapy between 04/01/2018 and 03/31/2020. iKnowMed electronic health records were used to examine timing of biomarker testing: before 1L therapy (cohort 1), after 1L therapy (cohort 2) or no testing (cohort 3). We assessed testing rates for ALK, BRAF, EGFR, ROS1, and PD-L1; use of full next-generation sequencing panel (NGS); time from mNSCLC diagnosis (dx) to 1L therapy; TAT from biomarker orders to results; and time from mNSCLC dx to test results. Results: We identified 3474 adults. Median age was 69 years (range 23-90), 51% female, 74% with adenocarcinoma and 76% with a documented ECOG performance status of 0 or 1. Testing rates are shown in table: 90% of pts had at least one biomarker test and 46% received all 5 biomarker tests. Changes in testing rates from 2018 to 2020 were 51% to 59% for BRAF, 71% to 71% for EGFR, 71% to 70% for ALK, 69% to 67% for ROS1, 82% to 84% for PD-L1, and 42% to 49% for pts tested for all 5 biomarkers. NGS testing increased from 33% to 44% (p<0.0001). The median (interquartile range [IQR]) time from mNSCLC dx to 1L therapy for all pts was 35 (22, 55) days. Median (IQR) TAT from biomarker testing orders to results ranged from 10 (6, 17) to 15 (10, 22) days for the individual biomarkers; and time from mNSCLC dx to biomarker results ranged from 14 (7, 26) to 21 (12, 36) days by biomarker. Conclusions: This real-world study showed that most pts received at least one biomarker test prior to 1L, but <50% received all 5 tests. NGS testing occurred in <50% of pts but increased over the periods examined. Median time from dx to 1L therapy was about 5 weeks and TAT from orders to results about 2 weeks. Analyses by histology and other trends will be reported. These data will be compared to the next phase of the MYLUNG study, which will evaluate contemporary ordering practices and TATs prospectively[Table: see text]

Determination of essential biomarkers in lung cancer: a real-world data study in Spain.

“…Compared with other countries, Spain accounts for a similar global positivity rate, as the 42% observed in an Italian study 10 and 42.9% in a German study 11 , as well as individually the positivity rates by biomarker. Likewise, determining at least one biomarker is similar to the German experience and to the real-life data reported from the USA 12 .…”

Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer

“…When an oncogene-based therapy is identified, a number of these subtypes have a prevalence of less than 5%. Additionally, a recent analysis showed that less than 50% of patients with metastatic NSCLC do not have their tumors tested broadly for genomic aberrations, missing treatment opportunities with small molecules [28].…”

Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective

“…In the Spanish Lung Cancer Biomarker Testing Registry study, ALK was not tested in 20% of cases, and ROS1 was not tested in over 40% of cases [23]. The situation is similar in the USA, as shown by a recent study by the MYLUNG Consortium TM , which demonstrated that most patients (90%) received testing for at least one out of five biomarkers (EGFR, ALK, ROS1, BRAF, and PD-L1) prior to first-line therapy, whereas less than half had testing for all five [24]. In this study, the median time from diagnosis to first-line therapy was approximately five weeks, and the turnaround time from testing orders to results was approximately two weeks.…”